CIK 0001540159 · Non-accelerated filer<br>Smaller reporting company
Edesa Biotech, Inc.
Sign in to watch- Ticker
- EDSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- (905) 475-1234
- Business address
- C/O FASKEN MARTINEAU DUMOULIN LLP, 333 BAY STREET, SUITE 2400, TORONTO, Ontario, Canada, M5H 2T6
- Former names
- Stellar Biotechnologies, Inc.
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 4 Open-market buy Chief Executive Officer bought 50,571 shares at an average $1.96 ($99,176)
- 4 Grant or award Chief Executive Officer acquired 82,236 shares (grant or award)
- 8-K Event Other events
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Grant or award Chief Executive Officer acquired 11,168 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 10,444 shares (grant or award)
- 8-K Event Other events
- 424B5 Offering Prospectus
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Grant or award Chief Executive Officer acquired 8,766 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 6,968 shares (grant or award)
- 8-K Event Other events
- 4 Grant or award Chief Executive Officer acquired 5,908 shares (grant or award)
- 8-K Event Material agreement · New debt or obligation
Page 4 of 38 · 753 filings